Fas and its ligand (FasL) play an important role in apoptosis and carcinogenesis. Therefore, the potential association of polymorphisms in the Fas (-670A>G, rs1800682; -1377G>A, rs2234767) and FasL (-844C>T, rs763110) with cancer risk has been widely investigated. However, all the currently available results are not always consistent. In this work, we performed a meta-analysis to further determine whether carriers of the polymorphisms in Fas and FasL of interest could confer an altered susceptibility to cancer. All relevant data were retrieved by PubMed and Web of Science, and 52 eligible studies were chosen for this meta-analysis. There was no association of the Fas -670A>G polymorphism with cancer risk in the pooled data. For the Fas -1377G>A and FasL -844C>T polymorphisms, results revealed that the homozygotes of -1377A and -844C were associated with elevated risk of cancer as a whole. Further stratified analysis indicated markedly increased risk for developing breast cancer, gastric cancer, and esophageal cancer, in particular in Asian population. We conclude that carriers of the Fas-1377A and the FasL -844C are more susceptible to the majority of cancers than non-carriers.
References
[1]
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78–85. doi: 10.1056/nejm200007133430201
[2]
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, et al. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233–243. doi: 10.1016/0092-8674(91)90614-5
[3]
Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, et al. (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267: 10709–10715.
[4]
Kang S, Dong SM, Seo SS, Kim JW, Park SY (2008) FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180: 1–5. doi: 10.1016/j.cancergencyto.2007.09.002
[5]
Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, et al. (2005) Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer 15 Suppl 3282–290. doi: 10.1111/j.1525-1438.2005.00433.x
[6]
Sun T, Zhou Y, Li H, Han X, Shi Y, et al. (2005) FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202: 967–974. doi: 10.1084/jem.20050707
[7]
Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, et al. (2005) Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 99: 113–118. doi: 10.1016/j.ygyno.2005.05.010
[8]
Dybikowska A, Sliwinski W, Emerich J, Podhajska AJ (2004) Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 14: 475–478. doi: 10.3892/ijmm.14.3.475
[9]
Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, et al. (2003) Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103: 221–225. doi: 10.1002/ijc.10800
[10]
Zhang W, Li C, Wang J, He C (2012) Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59: 141–146. doi: 10.5754/hge11300
[11]
Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, et al. (2011) Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet 12: 112. doi: 10.1186/1471-2350-12-112
[12]
Liu L, Wu C, Wang Y, Zhong R, Wang F, et al. (2011) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 32: 336–342. doi: 10.1093/carcin/bgq264
[13]
Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, et al. (2010) Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 25: 555–561. doi: 10.1111/j.1440-1746.2009.06116.x
[14]
Wang M, Wu D, Tan M, Gong W, Xue H, et al. (2009) FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 47: 559–568. doi: 10.1007/s10528-009-9264-0
[15]
Hsu PI, Lu PJ, Wang EM, Ger LP, Lo GH, et al. (2008) Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res 28: 97–103.
[16]
Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, et al. (2013) Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One 8: e53075. doi: 10.1371/journal.pone.0053075
[17]
Wang W, Zheng Z, Yu W, Lin H, Cui B, et al. (2012) Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 3: 625–628. doi: 10.3892/ol.2011.541
[18]
Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L (2012) FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population. Hum Immunol 73: 932–938. doi: 10.1016/j.humimm.2012.06.001
[19]
Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, et al. (2007) Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28: 2548–2551. doi: 10.1093/carcin/bgm211
[20]
Zhang B, Sun T, Xue L, Han X, Lu N, et al. (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28: 1067–1073. doi: 10.1093/carcin/bgl250
[21]
Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H (2004) Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: : 1478–1479; author reply 1479.
[22]
Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, et al. (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29: 2147–2152. doi: 10.1093/carcin/bgn205
[23]
Gormus U, Ergen A, Yaylim-Eraltan I, Yilmaz H, Turna A, et al. (2007) Fas-1377 A/G polymorphism in lung cancer. In Vivo 21: 663–666.
[24]
Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, et al. (2006) Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 54: 303–308. doi: 10.1016/j.lungcan.2006.09.002
[25]
Zhang X, Miao X, Sun T, Tan W, Qu S, et al. (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42: 479–484. doi: 10.1136/jmg.2004.030106
[26]
Holm K, Melum E, Franke A, Karlsen TH (2010) SNPexp - A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics 11: 600. doi: 10.1186/1471-2105-11-600
[27]
He J, Qiu LX, Wang MY, Hua RX, Zhang RX, et al. (2012) Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet 131: 1235–1244. doi: 10.1007/s00439-012-1152-8
[28]
The International HapMap Project. Nature 426: 789–796.
[29]
Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315: 848–853. doi: 10.1126/science.1136678
[30]
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188. doi: 10.1016/0197-2456(86)90046-2
[31]
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
[32]
Bye H, Prescott NJ, Matejcic M, Rose E, Lewis CM, et al. (2011) Population-specific genetic associations with oesophageal squamous cell carcinoma in South Africa. Carcinogenesis 32: 1855–1861. doi: 10.1093/carcin/bgr211
[33]
Ho T, Li G, Zhao C, Zheng R, Wei Q, et al. (2008) Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: a case-control analysis. Head Neck 30: 297–305. doi: 10.1002/hed.20699
[34]
Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, et al. (2006) Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer 16 Suppl 1179–182. doi: 10.1111/j.1525-1438.2006.00505.x
[35]
Kordi Tamandani DM, Sobti RC, Shekari M (2008) Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol 35: 183–186. doi: 10.1007/s00404-007-0504-4
[36]
Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, et al. (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12: 5596–5602. doi: 10.1158/1078-0432.ccr-05-1739
[37]
Bel Hadj Jrad B, Mahfouth W, Bouaouina N, Gabbouj S, Ahmed SB, et al. (2006) A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 233: 21–27. doi: 10.1016/j.canlet.2005.02.037
[38]
Shao P, Ding Q, Qin C, Wang M, Tang J, et al. (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71: 1122–1130. doi: 10.1002/pros.21328
[39]
Yang M, Sun T, Wang L, Yu D, Zhang X, et al. (2008) Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14: 3230–3236. doi: 10.1158/1078-0432.ccr-08-0177
[40]
Andera L (2009) Signaling activated by the death receptors of the TNFR family. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153: 173–180. doi: 10.5507/bp.2009.029
[41]
Kim R, Emi M, Tanabe K, Uchida Y, Toge T (2004) The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100: 2281–2291. doi: 10.1002/cncr.20270
[42]
Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, et al. (1998) Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101: 2579–2588. doi: 10.1172/jci1518
[43]
Crnogorac-Jurcevic T, Efthimiou E, Capelli P, Blaveri E, Baron A, et al. (2001) Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20: 7437–7446. doi: 10.1038/sj.onc.1204935
[44]
Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189–1192. doi: 10.1126/science.270.5239.1189
[45]
Strand S, Hofmann WJ, Hug H, Muller M, Otto G, et al. (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells–a mechanism of immune evasion? Nat Med 2: 1361–1366. doi: 10.1038/nm1296-1361
[46]
Reichmann E (2002) The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 12: 309–315. doi: 10.1016/s1044-579x(02)00017-2
[47]
Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, et al. (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63: 4327–4330.
[48]
Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34: 577–582. doi: 10.1016/s0161-5890(97)00081-3
[49]
Wu J, Metz C, Xu X, Abe R, Gibson AW, et al. (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170: 132–138. doi: 10.4049/jimmunol.170.1.132
[50]
Shao P, Ding Q, Qin C, Wang M, Tang J, et al. (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate.
[51]
Mandal RK, Mittal RD (2012) Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population? Urol Oncol 30: 555–561. doi: 10.1016/j.urolonc.2010.05.006
[52]
Zucchi F, da Silva ID, Ribalta JC, de Souza NC, Speck NM, et al. (2009) Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol 30: 142–144.
[53]
Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, et al. (2007) Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 121: 2451–2457. doi: 10.1002/ijc.22989
[54]
Ikehara SK, Ikehara Y, Matsuo K, Hirose K, Niwa T, et al. (2006) A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population. J Hum Genet 51: 927–933. doi: 10.1007/s10038-006-0040-2
[55]
Wang LE, Cheng L, Spitz MR, Wei Q (2003) Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 42: 1–8. doi: 10.1016/s0169-5002(03)00276-9
[56]
Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, et al. (2007) Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev 31: 225–232. doi: 10.1016/j.cdp.2007.04.005
[57]
Sun T, Miao X, Zhang X, Tan W, Xiong P, et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1030–1036. doi: 10.1093/jnci/djh187
[58]
Qureshi A, Nan H, Dyer M, Han J (2010) Polymorphisms of FAS and FAS ligand genes and risk of skin cancer. J Dermatol Sci 58: 78–80. doi: 10.1016/j.jdermsci.2010.01.003
[59]
Zhang H, Sun XF, Synnerstad I, Rosdahl I (2007) Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 13: 233–237. doi: 10.1097/ppo.0b013e318046f214
[60]
Li C, Larson D, Zhang Z, Liu Z, Strom SS, et al. (2006) Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16: 253–263. doi: 10.1097/01.fpc.0000199501.54466.de
[61]
Nelson HH, Kelsey KT, Bronson MH, Mott LA, Karagas MR (2001) Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol Biomarkers Prev 10: 809–810.
[62]
Li Y, Hao YL, Kang S, Zhou RM, Wang N, et al. (2013) Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol 128: 584–589. doi: 10.1016/j.ygyno.2012.12.002
[63]
Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, et al. (2007) Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res 27: 991–994.
[64]
Lima L, Morais A, Lobo F, Calais-da-Silva FM, Calais-da-Silva FE, et al. (2008) Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis 11: 94–98. doi: 10.1038/sj.pcan.4501002
[65]
Cao Y, Miao XP, Huang MY, Deng L, Lin DX, et al. (2010) Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49: 944–950. doi: 10.1002/mc.20676
[66]
Zhu Q, Wang T, Ren J, Hu K, Liu W, et al. (2010) FAS-670A/G polymorphism: A biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. Clin Chim Acta 411: 179–183. doi: 10.1016/j.cca.2009.10.024
[67]
Gangwar R, Mittal RD (2010) Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol 29: 349–356. doi: 10.1089/dna.2009.0982
[68]
Li C, Wu W, Liu J, Qian L, Li A, et al. (2006) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 16: 245–251. doi: 10.1097/01.fpc.0000194425.58511.a7
[69]
Zhu J, Qin C, Wang M, Yan F, Ju X, et al. (2010) Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol Carcinog 49: 810–817. doi: 10.1002/mc.20656
[70]
Wang LH, Ting SC, Chen CH, Tsai CC, Lung O, et al. (2010) Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 39: 155–161. doi: 10.1111/j.1600-0714.2009.00873.x
[71]
Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, et al. (2007) Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol 29: 815–821. doi: 10.1097/mph.0b013e3181581506
[72]
Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Ertan Y, et al. (2007) Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J Endocrinol Invest 30: 411–416. doi: 10.1007/bf03346319
